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In this issue of SQUMJ, Hamadeh et al. report on the epidemiology of female breast cancer in the Bahraini population with a total 
of 1,005 cases diagnosed over an 11-year period.1 
The authors report the age-standardised incidence 
rate of 58.2 per 100,000 population in 2000 and 44.4 
per 100,000 in 2010. The median age at diagnosis 
was 49 years and the five-year survival rate was 63%. 
This article raises a number of important issues. 
The incidence in Bahrain is midway between that of 
developed and less-developed countries, while the 
mean age at diagnosis is lower than Western countries, 
and survival is somewhat inferior to that reported 
from most developed countries. 
The incidence of cancer is rising across the globe. 
The International Agency for Research on Cancer 
(IARC) publishes data in a series of reports called 
GLOBOCAN. A comparison of the latest two versions 
(2008 and 2012) shows that the number of new cancer 
cases increased from 12.7 million in 2008 to 14.1 
million in 2012.2,3 Breast cancer remains the most 
common cancer among females and the second most 
common cancer overall, with an estimated 1.7 million 
new cases diagnosed in 2012. These account for more 
than a quarter of all the cases of cancer diagnosed in 
women. The incidence has increased by more than 
20% since 2008.4 Subsequent publication of the 2014 
World Cancer Report confirmed that, regrettably, the 
earlier forecasts correspond to the actual numbers.5 If 
this trend were to continue, the total number of new 
cancers would increase to an alarming 22 million by 
the year 2025. The mortality is expected to increase to 
13 million at that stage. A catastrophe is looming and 
urgent action is required.
What is even more alarming is the fact that 
there is a palpable divide between regions with a 
high incidence or a low incidence of cancer, and this 
generally corresponds to their affluence. The age-
standardised incidence rate of 268 cases per 100,000 
population in the more developed regions, compares 
to 148 cases per 100,000 in the less developed regions.4 
However, in terms of actual numbers, 43% of all cancers 
develop in resource-rich developed regions and 57% in 
resource-strapped less developed regions. While the 
increasing incidence of cancer in developed countries 
roughly corresponds to the increasing median age of 
population, the increasing numbers simply outgrow 
the median age in the less developed regions. This 
is also reflected in cancer-associated mortality. 
About 70% of cancer-associated deaths occur in less 
developed regions.4,5 
The incidence of breast cancer reflects the 
overall cancer situation. In women, the overall 
age-standardised rate for breast cancer is 43.3 per 
100,000, with 74.1 cases per 100,000 in developed 
countries, and 31.3 cases per 100,000 population in 
less developed countries.3 Compared to the incidence 
rate of around 90 cases per 100,000 female population 
in the USA, Hamadeh et al. reported an incidence rate 
of 44.4–58.2 cases per 100,000 women in Bahrain.1 
The current incidence rate in Oman is 25.5 cases per 
100,000 population.6
Although the current incidence rate in Oman is 
towards the lower end of the spectrum in the Gulf 
Cooperation Council (GCC) countries, it is the 
increase in the incidence and the total number of 
cases which is of concern. For example, in Oman, the 
age-standardised incidence rate of breast cancer has 
progressively increased from 13.8 in 1999, to 21.8 in 
2005 and then to 25.5 in 2011. In 2011 alone, a total of 
147 cases of breast cancer were diagnosed out of 573 
new cases (25.6%). This is in comparison with 38/389 
(14.9%) in 1999 and 95/422 (22.5%) in 2005.6 The reason 
for the increasing incidence remains unexplained. It 
could be either due to better detection and registration, 
e.g. the use of screening mammography, or an actual 
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increase in incidence. A total of 17 cases were detected 
using mammography over a four-year period between 
2009 and 2012 in Oman (personal communication 
with Hon. Ms. Yuthar Al-Rawahia, Chairperson, 
Oman Cancer Association); however, it is not clear 
how many of these patients already had a palpable 
lump and used the mobile mammography unit for 
diagnosis. Conversely, it is also not known how many 
patients may have travelled abroad for treatment and 
whose data therefore may not been captured by the 
National Tumour Registry. Clearly, this small number 
of cases does not explain the increased number of 
breast cancer cases diagnosed in the last few years.
The data from Bahrain is in many ways similar 
to that reported from Oman. Hamadeh et al. 
reported a median age at diagnosis of 49 years, 
compared to 48.5 years reported by Al Moundhri 
et al.7 and 47.4 years reported by Kumar et al.8 
It should be noted that in the two studies from 
Oman 50.7% and 60.4% patients presented with 
stage III/IV disease, respectively.7,8 The problem of 
countries in the region is more or less similar: younger 
age, advanced stage, and hence compromised overall 
survival. 
So what can we do? Like many other cancers, 
breast cancer can be tackled along the continuum of 
care at different stages—by the application of effective 
strategies for treatment and cure, early detection and 
prevention.9
The role of chemotherapy and hormone therapy 
(in the case of estrogen-receptor-positive tumours) 
is well established and the standard of care. However, 
a significant number of cancers still relapse. Over the 
last decade, important advances have led to better 
cure rates with the use of monoclonal antibodies, 
tyrosine kinase inhibitors and more recently chemo-
immunoconjugates. However, the treatment has 
become extremely expensive and out of reach 
for the vast majority of patients, especially in less 
developed countries. Even in developed countries, the 
exploding cost of new agents is now causing problems. 
Economists have questioned the sustainability of the 
model of evaluating and marketing new cancer drugs.
Early detection programmes using mammography 
have been in place for more than three decades. 
Although an earlier meta-analysis of randomised 
controlled trials showed a relative reduction in 
death from breast cancer,10 more recently, the role 
of screening mammography has been questioned.11 
While, a significantly higher number of early-stage 
breast cancers are diagnosed by this method, the 
advantage is offset by over-diagnosis and, in several 
instances, over-treatment. Over-diagnosis may 
account for 20–30% of cancers detected,12 while 
screening has not been shown to decrease the rate of 
detection of advanced cancers.13 A recently concluded 
randomised trial showed that screening did not reduce 
mortality from breast cancer.11 Furthermore, the 
cost-benefit ratio of screening mammography in low 
incidence countries augurs against its routine use.14 As 
a result, there has been a strong motion amongst the 
oncology community to reassess the need for breast 
cancer screening.
Overcoming the increasing incidence and 
subsequent mortality of breast cancer by prevention 
is a possible option. Primary prevention by lifestyle 
modification is an attractive and, in many cases, 
an achievable target. The three major initiatives in 
this regard have been the European Prospective 
Investigation into Cancer and Nutrition (EPIC) study,15 
the ViTamins And Lifestyle (VITAL) study16 and the 
recommendations of the World Cancer Research 
Fund/American Institute for Cancer Research (WCRF/
AICR).17 The EPIC is an ongoing prospective cohort 
study, initiated in 1992 in 10 European countries. 
Dietary assessment is mainly carried out through a 
self-administered, semi-quantitative food frequency 
questionnaire and information on a wide range of 
lifestyle factors and anthropometric measurements 
are collected. In the VITAL study, the participants 
complete a detailed questionnaire on supplement 
use, diet and risk factors for cancers, and the cohort 
is prospectively followed-up for the incidence of 
cancers. In 2007, the WCRF/AICR released a set of 
recommendations on diet, physical activity and weight 
management for cancer prevention on the basis of the 
then available evidence.16
Risk factors for breast cancer are different for the pre 
and postmenopausal population.4 For premenopausal 
breast cancer, there is convincing evidence that 
consuming alcohol increases the risk, whereas lactation 
protects against it. For postmenopausal breast cancer, 
there is convincing evidence that the consumption 
of alcohol, body fatness and adult-attained height 
increase the risk, whereas, lactation and physical 
activity protects against it. Many of these factors are 
modifiable. However, the question is whether lifestyle 
modifications actually lead to a reduction in the 
incidence of breast cancer. More recently, answers 
have begun to emerge. The EPIC investigators have 
reported that a greater concordance with the WCRF/
AICR recommendations (for example: weight loss, 
physical activity and avoidance of sugar, salt, alcohol 
and red meat) was significantly associated with a 
decreased risk of cancer. A one-point increment was 
associated with a 5% risk reduction for all cancers.18 
In the VITAL study, the breast cancer risk was found 
to be reduced by 60% in women who met at least 
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five of the recommendations, compared with those 
who met only one.19 The reduction in mortality was 
demonstrated by the EPIC investigators, who reported 
that participants with maximum adherence to the 
WCRF recommendations had a 34% reduced risk of 
death compared with those who had least adherence 
to them.20
In conclusion, the incidence of breast cancer is 
on the increase worldwide. Although the incidence 
is lower in less developed countries, it is rapidly 
increasing and so is mortality. Early detection through 
screening is not widely available in many countries 
or may not be relevant. Genetic studies may help to 
identify families with increased risk, who could then 
be offered early detection. However, these remain 
a small sub-set and account for no more than 5% 
of all breast cancer cases. The cost of the treatment 
has increased spectacularly and many patients or 
governments cannot or would not be able to afford it. 
Primary prevention through lifestyle modification is 
an attractive cost-effective option. However, if primary 
prevention measures were to be adopted to combat 
the rising incidence and mortality, this would require 
a coordinated campaign. At the moment, cancer is 
not considered a major problem in less developed 
countries. There is an urgent need to remedy this 
opinion. Future breast cancer outcomes will be 
determined by recognition of the problem; creating 
awareness not only by the advocacy groups, but 
also by the physicians; widespread dissemination of 
information through both print and electronic media, 
and the will of the policy-makers.
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